Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson

New England Journal of Medicine, 2006

Oregon Health & Science University, Centre Hospitalier Universitaire de Poitiers, Newcastle University, Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Heinrich Heine University Düsseldorf, Leipzig University, Cornell University, National Heart Lung and Blood Institute, Dana-Farber Cancer Institute, Hospital Clínic de Barcelona, Heidelberg University, Atrium Health Wake Forest Baptist, Icahn School of Medicine at Mount Sinai, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Bordeaux, Erasmus MC, Royal Adelaide Hospital, Medical University of Vienna, Johannes Gutenberg University Mainz, Universitair Ziekenhuis Leuven, Vancouver General Hospital, Ospedale San Luigi Gonzaga, University Hospital of Basel, Cancer Research Center, Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa, Fred Hutch Cancer Center, Uppsala University Hospital, Mater Adult Hospital, Policlinico S.Orsola-Malpighi, Novartis (United States), University of Chicago

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3467

Citations

View on Google Scholar

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Abstract

Journal Details

Join JournalsHub

Welcome Back